Drug Approval | June 02, 2026
Bristol Myers Squibb wins EU approval for Opdivo-based frontline treatment in advanced hodgkin lymphoma
The approval is supported by results from the Phase 3 SWOG 1826 trial
The approval is supported by results from the Phase 3 SWOG 1826 trial
While overall survival data remain immature, the results pointed to a favourable trend.
Based in the global marketing function, he will be responsible for strengthening the company's visibility among sponsors, partners and industry stakeholders worldwide
Real-time remote collaboration during robotic-assisted cholecystectomy showcases new possibilities for surgical mentoring, education, and knowledge sharing across institutions
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
Seasoned HR leader brings over 15 years of experience in global talent strategy, organizational transformation, and workforce planning
The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
